西非HIV感染者立即或延迟启动ART的病毒学失败与耐药比较
Temprano试验纳入CD4计数较高的未治疗HIV感染成人,随机分为立即启动ART组与延迟至符合WHO标准再启动ART组。ART启动30个月后,延迟组病毒学失败率更高(35.3%对29.9%,P=0.04),基因型敏感性评分更低(P=0.04)。结论为早期启动ART可降低中期病毒学失败与耐药风险。
要点
- CD4较高的无症状HIV感染者早期启动ART可降低中期病毒学失败风险。
- 延迟启动者ART后30个月病毒学失败率35.3%,高于立即组的29.9%。
- 在病毒载量监测和药物线数有限的国家,早期启动的获益尤为重要。
核心结论
- 在CD4计数较高的HIV感染成人中,早期启动ART可降低中期病毒学失败和耐药风险。
研究设计与样本
- Temprano随机试验,2056例未治疗HIV感染成人随机分为立即启动ART组1033例与延迟启动ART组1023例,随访30个月。
主要发现
- 延迟组中488例在试验随访期间启动ART,其基线中位CD4为280对465 cells/mm3,中位血浆HIV-1 RNA为5.1对4.7 log10 copies/mL。
- ART启动30个月后,延迟组病毒学失败率高于立即组(35.3%对29.9%,P=0.04),基因型敏感性评分更低(P=0.04)。
临床怎么用
- 对CD4计数较高的HIV感染者可考虑尽早启动ART,以降低中期病毒学失败与耐药风险,尤其在病毒载量监测和药物线数有限的环境。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Asymptomatic HIV-infected people who start ART early may feel less motivated and neglect compliance. This might promote the emergence of resistance. METHODS: In the Temprano trial, ART-naive HIV-infected adults with high CD4 counts were randomly assigned to start ART immediately (immediate group) or defer ART until the WHO criteria were met (deferred group). All participants were monitored for 30 months. Those in the deferred group who started ART were monitored for longer, until they had completed 30 months on ART. We compared the rate of virological failure and drug resistance between the immediate and deferred groups 30 months after ART initiation. RESULTS: Of the 2056 participants in Temprano, 1033 were assigned to start ART immediately and 1023 to defer ART. Of the latter, 488 started ART during trial follow-up. Patients in the deferred group who started ART had a lower median CD4 count (280 versus 465 cells/mm3) and a higher median plasma HIV-1 RNA (5.1 versus 4.7 log10 copies/mL) at baseline. During follow-up, participants in both groups had similar antiretroviral drug exposure. Thirty months after ART initiation, patients in the deferred group had a higher rate of virological failure (35.3% versus 29.9%, P = 0.04) and a lower genotypic susceptibility score (P = 0.04). CONCLUSIONS: Starting ART early decreases the risk of virological failure and drug resistance in the medium term. This benefit is of particular importance in countries where access to viral load monitoring and the number of antiretroviral drug lines is limited.
引用
- Gabillard D, N'Takpé JB, Chaix ML, et al. Virological failure and drug resistance in West African HIV-infected adults who started ART immediately or deferred ART initiation. J Antimicrob Chemother. 2021. PMID: 34533197. doi:10.1093/jac/dkab225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。